{
    "nctId": "NCT01201265",
    "briefTitle": "A Study of Bevacizumab in Combination With Gemcitabine and Carboplatin in Participants With Triple Negative Metastatic Breast Cancer",
    "officialTitle": "A Multi Centre, Pilot Phase II Trial Assessing the Efficacy and Safety of Bevacizumab + Gemcitabine + Carboplatin as First Line Treatment for Patients Diagnosed With Triple Negative Metastatic Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 40,
    "primaryOutcomeMeasure": "Progression-free Survival (PFS)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Female participants, \\>/= 18 years of age\n* Metastatic breast cancer\n* Estrogen receptor-, progesterone- and human epidermal growth factor receptor 2 (HER2)-negative disease\n* Treatment-na\u00efve for metastatic breast cancer\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-2\n* Adequate hematological, renal and liver function\n* Patients should have received Anthracyclines and Taxanes in the adjuvant setting\n* Women of childbearing potential must agree to use adequate contraception (per institutional standard of care) during treatment and until 6 months after the last administration of investigational products\n\nExclusion Criteria:\n\n* Prior first line treatment for metastatic breast cancer\n* Central nervous system (CNS) metastasis\n* Uncontrolled hypertension (\\> 170/95 mmHg)\n* Evidence of bleeding diathesis, coagulopathy or hemorrhage at baseline\n* Other malignancy within the last 5 years, except for adequately treated carcinoma in situ of the cervix or squamous carcinoma of the skin, or adequately controlled limited basal cell skin cancer.\n* Prior therapy with gemcitabine or carboplatin in the metastatic setting. Participants having received gemcitabine or carboplatin as part of adjuvant therapy are eligible, if recurrence was first documented \\>6 months after the last exposure to the drug(s)\n* Requirement of chronic use of immunosuppressive agents\n* HIV, hepatitis B or hepatitis C infection",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}